Free Trial

Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix logo
$12.21 +0.29 (+2.43%)
Closing price 04:00 PM Eastern
Extended Trading
$12.20 -0.01 (-0.08%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OCUL vs. RVMD, GRFS, TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, and PCVX

Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Ocular Therapeutix vs. Its Competitors

Revolution Medicines (NASDAQ:RVMD) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Revolution Medicines had 3 more articles in the media than Ocular Therapeutix. MarketBeat recorded 6 mentions for Revolution Medicines and 3 mentions for Ocular Therapeutix. Revolution Medicines' average media sentiment score of 0.99 beat Ocular Therapeutix's score of 0.63 indicating that Revolution Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ocular Therapeutix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ocular Therapeutix has higher revenue and earnings than Revolution Medicines. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$11.58M609.64-$600.09M-$4.00-9.48
Ocular Therapeutix$63.72M30.53-$193.51M-$1.15-10.62

Revolution Medicines has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. Revolution Medicines' return on equity of -37.06% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -37.06% -32.84%
Ocular Therapeutix -323.09%-59.92%-41.98%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Revolution Medicines has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Revolution Medicines currently has a consensus target price of $68.91, suggesting a potential upside of 81.82%. Ocular Therapeutix has a consensus target price of $17.33, suggesting a potential upside of 41.96%. Given Revolution Medicines' higher possible upside, equities research analysts clearly believe Revolution Medicines is more favorable than Ocular Therapeutix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ocular Therapeutix
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Revolution Medicines beats Ocular Therapeutix on 11 of the 15 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUL vs. The Competition

MetricOcular TherapeutixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.90B$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-10.629.0528.1020.06
Price / Sales30.53580.15428.2490.60
Price / CashN/A165.2136.2258.56
Price / Book6.075.168.665.87
Net Income-$193.51M$30.99M$3.25B$258.55M
7 Day Performance7.77%7.74%4.20%2.23%
1 Month Performance32.86%16.18%10.82%12.76%
1 Year Performance47.46%-1.03%34.70%19.36%

Ocular Therapeutix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUL
Ocular Therapeutix
3.8788 of 5 stars
$12.21
+2.4%
$17.33
+42.0%
+50.7%$1.90B$63.72M-10.62230
RVMD
Revolution Medicines
4.5042 of 5 stars
$38.37
+0.9%
$68.00
+77.2%
-20.0%$7.15B$11.58M-9.59250
GRFS
Grifols
3.3022 of 5 stars
$9.72
-0.2%
$10.30
+6.0%
+28.6%$6.68B$7.81B8.3123,822Upcoming Earnings
TGTX
TG Therapeutics
3.6933 of 5 stars
$38.92
+5.0%
$43.80
+12.5%
+86.6%$6.18B$329M162.17290Positive News
NUVL
Nuvalent
3.3926 of 5 stars
$84.59
+4.5%
$119.60
+41.4%
+2.2%$6.07BN/A-19.2740
LNTH
Lantheus
4.7008 of 5 stars
$83.06
+2.2%
$131.20
+58.0%
-37.6%$5.75B$1.53B23.60700Positive News
RYTM
Rhythm Pharmaceuticals
3.1129 of 5 stars
$89.15
+2.8%
$91.00
+2.1%
+76.9%$5.67B$130.13M-31.73140
AXSM
Axsome Therapeutics
4.7417 of 5 stars
$112.33
+3.1%
$172.33
+53.4%
+23.2%$5.53B$385.69M-19.47380Analyst Revision
TLX
Telix Pharmaceuticals
N/A$15.57
-2.5%
$22.33
+43.4%
N/A$5.27B$783.21M0.00N/ANews Coverage
Analyst Revision
CRSP
CRISPR Therapeutics
2.5305 of 5 stars
$56.42
-0.7%
$71.75
+27.2%
+19.3%$4.87B$37.31M-12.48460Analyst Forecast
Gap Up
PCVX
Vaxcyte
1.8056 of 5 stars
$36.38
+1.3%
$136.50
+275.2%
-57.4%$4.69BN/A-9.12160News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners